% alzhub.org library filter
% Source: https://alzhub.org/research?institution=I4210148122
% 9 entries, in the order the page lists them. Built from alzhub.org's own records.
% 0 entries have no readable author in the source record and carry no author field.

@article{swanson2021-33865446,
  author  = {Swanson, C. J. and Zhang, Y. and Dhadda, S. and Wang, J. and Kaplow, J. and Lai, R. Y. K. and Lannfelt, L. and Bradley, H. and others},
  title   = {{A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody}},
  journal = {Alzheimer's research \& therapy},
  year    = {2021},
  doi     = {10.1186/s13195-021-00813-8},
  pmid    = {33865446},
  url     = {https://doi.org/10.1186/s13195-021-00813-8}
}

@article{vandyck2023-36449413,
  author  = {van Dyck, C. H. and Swanson, C. J. and Aisen, P. and Bateman, R. J. and Chen, C. and Gee, M. and Kanekiyo, M. and Li, D. and others},
  title   = {{Lecanemab in Early Alzheimer's Disease}},
  journal = {The New England journal of medicine},
  year    = {2023},
  doi     = {10.1056/nejmoa2212948},
  pmid    = {36449413},
  url     = {https://doi.org/10.1056/nejmoa2212948}
}

@article{honig2024-38730496,
  author  = {Honig, L. S. and Sabbagh, M. N. and van Dyck, C. H. and Sperling, R. A. and Hersch, S. and Matta, A. and Giorgi, L. and Gee, M. and others},
  title   = {{Updated safety results from phase 3 lecanemab study in early Alzheimer's disease}},
  journal = {Alzheimer's research \& therapy},
  year    = {2024},
  doi     = {10.1186/s13195-024-01441-8},
  pmid    = {38730496},
  url     = {https://doi.org/10.1186/s13195-024-01441-8}
}

@article{dubois2012-22915447,
  author  = {Dubois, B. and Tolosa, E. and Katzenschlager, R. and Emre, M. and Lees, A. J. and Schumann, G. and Pourcher, E. and Gray, J. and others},
  title   = {{Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study}},
  journal = {Movement disorders : official journal of the Movement Disorder Society},
  year    = {2012},
  doi     = {10.1002/mds.25098},
  pmid    = {22915447},
  url     = {https://doi.org/10.1002/mds.25098}
}

@article{rawal2025-40673737,
  author  = {Rawal, S. and Wildsmith, K. R. and Aluri, J. and Yagi, T. and Chang, M. K. and Niu, H. and Zhou, J. and Horie, K. and others},
  title   = {{An Anti-tau Therapeutic Antibody Etalanetug (E2814): A Phase 1, First-in-human (FIH) Study of Single and Multiple Ascending Doses in Healthy Subjects}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2025},
  doi     = {10.1097/wad.0000000000000680},
  pmid    = {40673737},
  url     = {https://doi.org/10.1097/wad.0000000000000680}
}

@article{vandyck2025-41355080,
  author  = {van Dyck, C. H. and Sperling, R. and Johnson, K. and Dhadda, S. and Kanekiyo, M. and Li, D. and Gee, M. and Hersch, S. and Irizarry, M. and Kramer, L.},
  title   = {{Long-term safety and efficacy of lecanemab in early Alzheimer's disease: Results from the Clarity AD open-label extension study}},
  journal = {Alzheimer's \& Dementia},
  year    = {2025},
  doi     = {10.1002/alz.70905},
  pmid    = {41355080},
  url     = {https://doi.org/10.1002/alz.70905}
}

@article{grill2024-37830926,
  author  = {Grill, J. D. and Flournoy, C. and Dhadda, S. and Ernstrom, K. and Sperling, R. and Molina-Henry, D. and Tranotti, K. and Harris, R. and others},
  title   = {{Eligibility Rates among Racially and Ethnically Diverse US Participants in Phase 2 and Phase 3 Placebo-Controlled, Double-Blind, Randomized Trials of Lecanemab and Elenbecestat in Early Alzheimer Disease}},
  journal = {Annals of neurology},
  year    = {2024},
  doi     = {10.1002/ana.26819},
  pmid    = {37830926},
  url     = {https://doi.org/10.1002/ana.26819}
}

@article{garciareitboeck2018-30157425,
  author  = {Garcia-Reitboeck, P. and Phillips, A. and Piers, T. M. and Villegas-Llerena, C. and Butler, M. and Mallach, A. and Rodrigues, C. and Arber, C. E. and others},
  title   = {{Human Induced Pluripotent Stem Cell-Derived Microglia-Like Cells Harboring TREM2 Missense Mutations Show Specific Deficits in Phagocytosis}},
  journal = {Cell reports},
  year    = {2018},
  doi     = {10.1016/j.celrep.2018.07.094},
  pmid    = {30157425},
  url     = {https://doi.org/10.1016/j.celrep.2018.07.094}
}

@article{doherty2022-35622461,
  author  = {Doherty, T. and Gee, M. and Maruff, P. and Smith, R. and Murphy, J. and Marsh, J. and Koschalka, L. and Martinez, M. and others},
  title   = {{Increasing the Cognitive Screening Efficiency of Global Phase III Trials in Early Alzheimer Disease: The Cognitive Task Force}},
  journal = {Alzheimer disease and associated disorders},
  year    = {2022},
  doi     = {10.1097/wad.0000000000000508},
  pmid    = {35622461},
  url     = {https://doi.org/10.1097/wad.0000000000000508}
}